SNN — Smith & Nephew plc stock price, charts and financials

Latest market price

32.15

+0.59+1.87%

Overview Short InterestFilings

SNNQT54Smith & Nephew plc·NYSE

Overview Short InterestFilings

32.15+1.87%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PEN+0.57%$323.02 ALGN+2.21%$172.89 PODD+2.63%$169.70 GMED+3.39%$81.46 GKOS+2.49%$170.87 BRKR+2.34%$64.31 ZBH+3.25%$96.98 MASI+0.00%$179.95

Snapshot

Index	-	P/E	21.11	EPS (ttm)	1.50	Insider Own	-	Shs Outstand	420.26M	Perf Week	3.24%

Market Cap	13.13B	Forward P/E	12.78	EPS next Y	2.47	Insider Trans	-	Shs Float	419.82M	Perf Month	9.85%

Enterprise Value	15.90B	PEG	0.39	EPS next Q	-	Inst Own	-	Short Float	1.07%	Perf Quarter	2.04%

Income	618.37M	P/S	2.09	EPS this Y	54.17%	Inst Trans	-	Short Ratio	3.33	Perf Half Y	-6.24%

Sales	6.29B	P/B	2.56	EPS next Y	11.25%	ROA	6.10%	Short Interest	4.51M	Perf YTD	-3.81%

Book/sh	-	P/C	10.58	EPS next 5Y	9.72%	ROE	11.79%	52W High	39.52 -18.64%	Perf Year	2.04%

Cash/sh	-	P/FCF	15.47	EPS past 3/5Y	42.28% 7.14%	ROIC	9.11%	52W Low	29.10 10.50%	Perf 3Y	0.90%

Dividend Est.	0.96 (3.00%)	EV/EBITDA	9.88	Sales past 3/5Y	5.81% 6.26%	Gross Margin	68.01%	Volatility	1.96% 1.90%	Perf 5Y	-26.43%

Dividend TTM	0.78 (2.43%)	EV/Sales	2.53	EPS Y/Y TTM	53.19%	Oper. Margin	16.27%	ATR (14)	0.77	Perf 10Y	-8.92%

Dividend Ex-Date	Mar 27, 2026	Quick Ratio	1.25	Sales Y/Y TTM	6.35%	Profit Margin	10.14%	RSI (14)	55.13	Recom	2.77

Dividend Gr. 3/5Y	0.53% 0.32%	Current Ratio	2.57	EPS Q/Q	2164.01%	SMA20	2.31%	Beta	0.59	Target Price	30.93

Payout	52.80%	Debt/Eq	0.63	Sales Q/Q	13.36%	SMA50	3.67%	Rel Volume	1.01	Prev Close	31.56

Employees	17,818	LT Debt/Eq	0.60	Earnings	Aug 04	SMA200	-3.56%	Avg Volume	1.49M	Price	32.15

IPO Date	Nov 16, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.34% 90.43%	Net Debt/EBITDA	1.72	Volume	1,508,165	Change	1.87%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-11-26	Reiterated	Bernstein	Market Perform	$36 → $32
May-11-26	Reiterated	Canaccord Genuity	Hold	$32 → $30
Apr-24-26	Reiterated	Canaccord Genuity	Hold	$35 → $32
Oct-14-25	Downgrade	Bernstein	Outperform → Market Perform	$38
Aug-18-25	Reiterated	Canaccord Genuity	Hold	$27 → $36
Mar-12-25	Downgrade	UBS	Buy → Neutral
Nov-04-24	Reiterated	Canaccord Genuity	Buy	$27
Jun-05-24	Upgrade	UBS	Neutral → Buy
Mar-04-22	Upgrade	Redburn Partners	Sell → Neutral
Dec-18-20	Upgrade	Bernstein	Market Perform → Outperform

Latest News

Jul-29-26

Jul-29-2610:02AM

Smith+Nephew's ESSA Spatial Surgery System Receives FDA's De Novo ClassificationBenzinga

Jul-23-26

Jul-23-2602:30PM

Smith+Nephew Expands ASC Platform to Support Value-Based Carezacks.com

Jul-16-26

Jul-16-2612:46PM

Smith+Nephew Launches LYNX COBLATION Wand for ENT Airway Surgeryzacks.com

Jul-14-26

Jul-14-2601:07PM

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for QuotationBenzinga

Jul-10-26

Jul-10-2611:03AM

Solving A Lackluster Growth Outlook Should Be Solventum's Next PrioritySeekingAlpha

Jul-09-26

Jul-09-2602:00AM

New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisionsglobenewswire.com

02:00AM

New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complicationsglobenewswire.com

Jun-25-26

Jun-25-2607:28AM

Smith & Nephew: Ongoing Business Progress And A More Attractive PriceSeekingAlpha

Jun-11-26

Jun-11-2609:12AM

Smith & Nephew plc (SNN) Shareholder/Analyst Call TranscriptSeekingAlpha

Company

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	6,164	6,164	5,810	5,549	5,215	5,212	4,560	5,138	4,904
Cost of Goods Sold Incl. D&A	1,957	1,957	1,731	1,654	1,515	1,514	1,381	1,331	1,298
Gross Profit	4,207	4,207	4,079	3,895	3,700	3,698	3,179	3,807	3,606
Selling, General and Administrative Excl. Other	3,036	3,036	2,904	2,834	2,707	2,637	2,439	2,534	2,384
Research and Development	346	346	343	339	345	356	307	292	246
Other Operating Expense	31	31	175	297	198	112	138	166	113
Operating Income	794	794	657	425	450	593	295	815	863
Interest Expense	157	141	150	133	80	80	62	65	59
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	142	126	-9	-2	-135	73	13	-7	-23
Net Income Before Taxes	779	779	498	290	235	586	246	743	781
Income Taxes	154	154	86	27	12	62	202	143	118
Consolidated Net Income	625	625	412	263	223	524	448	600	663
Net Income From Continuing Operations	625	625	412	263	223	524	448	600	663
Net Income	625	625	412	263	223	524	448	600	663
EPS (Recurring)	1.46	1.46	0.94	1.20	0.50	1.20	1.02	1.38	1.52
EPS (Basic, Before Extraordinaries)	1.46	1.46	0.94	1.20	0.50	1.20	1.02	1.38	1.52
EPS (Diluted)	1.44	1.44	0.94	1.20	0.50	1.20	1.02	1.36	1.52
EBITDA	1,336	1,336	1,335	1,214	1,150	1,219	927	1,427	1,403
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	22.33	22.78	26.15	22.73	53.78	28.85	41.34	35.35	24.59
Price To Sales Ratio	2.26	2.30	1.85	1.07	2.26	2.92	4.05	4.10	3.34
Gross Margin	68.25	68.25	70.21	70.19	70.95	70.95	69.71	74.09	73.53
Operating Margin	12.88	12.88	11.31	7.66	8.63	11.38	6.47	15.86	17.60
Net Margin	10.14	10.14	7.09	4.74	4.28	10.05	9.82	11.68	13.52
Shares Outstanding	433	433	438	218	438	439	438	438	438
Market Capitalization	13,921	14,207	10,766	5,947	11,778	15,198	18,470	21,055	16,372
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.